Insulet Co. (NASDAQ:PODD) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Insulet Co. (NASDAQ:PODD) have earned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $242.29.

Several research analysts have recently weighed in on PODD shares. Piper Sandler increased their price objective on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. UBS Group increased their price target on shares of Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research note on Friday, August 9th. BTIG Research upped their price objective on Insulet from $250.00 to $260.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Canaccord Genuity Group lifted their target price on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Finally, Raymond James boosted their price target on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th.

Institutional Trading of Insulet

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Angeles Wealth Management LLC acquired a new stake in shares of Insulet in the 3rd quarter valued at about $287,000. Harbor Capital Advisors Inc. lifted its holdings in Insulet by 12.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 2,290 shares of the medical instruments supplier’s stock worth $533,000 after buying an additional 261 shares during the last quarter. Janney Montgomery Scott LLC grew its position in shares of Insulet by 7.5% in the 3rd quarter. Janney Montgomery Scott LLC now owns 5,661 shares of the medical instruments supplier’s stock worth $1,318,000 after acquiring an additional 394 shares in the last quarter. Symmetry Partners LLC bought a new stake in shares of Insulet in the 3rd quarter valued at approximately $924,000. Finally, Stephens Investment Management Group LLC raised its position in shares of Insulet by 10.6% during the 3rd quarter. Stephens Investment Management Group LLC now owns 80,792 shares of the medical instruments supplier’s stock valued at $18,804,000 after acquiring an additional 7,726 shares in the last quarter.

Insulet Stock Down 0.4 %

Shares of NASDAQ PODD opened at $232.37 on Wednesday. The firm has a market cap of $16.29 billion, a P/E ratio of 42.25, a price-to-earnings-growth ratio of 4.36 and a beta of 1.21. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60. Insulet has a 1 year low of $128.68 and a 1 year high of $243.98. The firm’s 50 day moving average price is $224.27 and its 200 day moving average price is $200.35.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.01). The business had revenue of $488.50 million for the quarter, compared to analyst estimates of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. Insulet’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.38 EPS. As a group, sell-side analysts anticipate that Insulet will post 3.04 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.